- Home
- FOA vs ELDN Comparison
FOA vs ELDN Comparison
Compare FOA & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOA
- ELDN
- Stock Information
- Founded
- FOA 2013
- ELDN 2004
- Country
- FOA United States
- ELDN United States
- Employees
- FOA N/A
- ELDN 31
- Industry
- FOA Finance Companies
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- FOA Finance
- ELDN Health Care
- Exchange
- FOA Nasdaq
- ELDN Nasdaq
- Market Cap
- FOA 240.8M
- ELDN 176.1M
- IPO Year
- FOA N/A
- ELDN N/A
- Fundamental
- Price
- FOA $19.27
- ELDN $2.99
- Analyst Decision
- FOA Buy
- ELDN Strong Buy
- Analyst Count
- FOA 2
- ELDN 1
- Target Price
- FOA $26.25
- ELDN $16.00
- AVG Volume (30 Days)
- FOA 94.1K
- ELDN 249.0K
- Earning Date
- FOA 05-05-2025
- ELDN 05-08-2025
- Dividend Yield
- FOA N/A
- ELDN N/A
- EPS Growth
- FOA N/A
- ELDN N/A
- EPS
- FOA 1.27
- ELDN N/A
- Revenue
- FOA $338,171,000.00
- ELDN N/A
- Revenue This Year
- FOA $8.63
- ELDN N/A
- Revenue Next Year
- FOA $9.95
- ELDN N/A
- P/E Ratio
- FOA $15.13
- ELDN N/A
- Revenue Growth
- FOA 44.36
- ELDN N/A
- 52 Week Low
- FOA $4.10
- ELDN $1.55
- 52 Week High
- FOA $32.40
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- FOA 41.15
- ELDN 39.03
- Support Level
- FOA $18.86
- ELDN $2.63
- Resistance Level
- FOA $20.60
- ELDN $3.21
- Average True Range (ATR)
- FOA 1.41
- ELDN 0.24
- MACD
- FOA -0.00
- ELDN 0.03
- Stochastic Oscillator
- FOA 40.38
- ELDN 45.24
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to an range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.